• Register
  • Login

Canadian Journal of Medicine

  1. Home
  2. Necessity of Evaluation of Non-coding RNAs in Clinical Trial for Target Therapy

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Related Links

FAQ

Aims and Scope

Editorial Board

Peer Review Process

Indexing and Abstracting

News

Necessity of Evaluation of Non-coding RNAs in Clinical Trial for Target Therapy

    Author

    • Seyed Hassan Saadat

    Personalized Medicine Research Center, Tehran, Iran

,
10.33844/cjm.2019.60486
  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

Genomic and proteomic approaches have improved the understanding of the mechanisms
involved in cancer. Genomic mutations in cancer indicate that many mutations or altered copy
numbers in cancer often occur in non-coding regions of the DNA including microRNAs
(miRNAs), long noncoding RNAs (lncRNAs), small interfering RNAs (siRNAs), and antisense
RNAs (Li et al, 2017; Yoon & Rossi, 2018; Yu, Jian, Allan, & Tu, 2019).
Noncoding RNAs, including lncRNAs and miRNAs, are potential therapeutic targets because they
have the potential to be applied in the diagnosis and prognosis of a number of cancers. Furthermore,
their regulations are implicated in development and progression of many kinds of malignancies e.g.,
proliferation, invasion, metastasis, angiogenesis and drug resistance, thus suggesting its potential in
targeted therapy (Smolle, Calin, Pichler, & Calin, 2017; Vo et al., 2019; Zhang & Xin, 2018).
Therefore, RNA profiling using bioinformatics tools and the development of databases can be helpful
in development of targeted research in this regard, where in-depth understanding of their multiple
mechanisms will be helpful in clarifying their substantial role in regulation of many genes involved
in cancer. For instance, anti-miRNA oligonucleotides (AMO) are considered to be capable of
suppressing the function of oncomirs, leading to inhibition of tumor growth. Clinical trials and
increased success rates in noncoding RNAs therapy are considered to be an opportunity for cancer
treatment

  • XML
  • PDF 369.15 K
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • CHICAGO
  • VANCOUVER
    • Article View: 358
    • PDF Download: 291
Canadian Journal of Medicine
Volume 1, Issue 1
January 2019
Page 0-0
Files
  • XML
  • PDF 369.15 K
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • CHICAGO
  • VANCOUVER
Statistics
  • Article View: 358
  • PDF Download: 291

APA

Saadat, S. H. (2020). Necessity of Evaluation of Non-coding RNAs in Clinical Trial for Target Therapy. Canadian Journal of Medicine, 1(1), 0-0. doi: 10.33844/cjm.2019.60486

MLA

Saadat, S. H. . "Necessity of Evaluation of Non-coding RNAs in Clinical Trial for Target Therapy", Canadian Journal of Medicine, 1, 1, 2020, 0-0. doi: 10.33844/cjm.2019.60486

HARVARD

Saadat, S. H. (2020). 'Necessity of Evaluation of Non-coding RNAs in Clinical Trial for Target Therapy', Canadian Journal of Medicine, 1(1), pp. 0-0. doi: 10.33844/cjm.2019.60486

CHICAGO

S. H. Saadat, "Necessity of Evaluation of Non-coding RNAs in Clinical Trial for Target Therapy," Canadian Journal of Medicine, 1 1 (2020): 0-0, doi: 10.33844/cjm.2019.60486

VANCOUVER

Saadat, S. H. Necessity of Evaluation of Non-coding RNAs in Clinical Trial for Target Therapy. Canadian Journal of Medicine, 2020; 1(1): 0-0. doi: 10.33844/cjm.2019.60486

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Sitemap

News

  • PubMed, a practical free resource for medical students 2022-05-23
  • Tips on rules of publishing articles in journals 2022-01-13
  • What is the BEST title for your research paper? 2021-12-29
  • On paraphrasing 2021-12-23
  • United Nations SDG Publishers Compact 2021-12-20

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

©